Pharmanutra SpA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IT0005274094
EUR
53.00
-0.6 (-1.12%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Pharmanutra SpA stock-summary
stock-summary
Pharmanutra SpA
Pharmaceuticals & Biotechnology
Pharmanutra SpA is an Italy-based company engaged in the healthcare industry. The Company develops nutraceutical products and medical devices. It focuses on studying and producing formulations that are backed up in scientific research. It is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The Company offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.
Company Coordinates stock-summary
Company Details
Via delle Lenze n. 216/B , PISA None : 56122
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
26 Million
(Quarterly Results - Mar 2025)
Net Profit:
2 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 523 Million ()

stock-summary
P/E

28.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.02%

stock-summary
Debt Equity

0.18

stock-summary
Return on Equity

25.79%

stock-summary
Price to Book

7.91